Immunization Service Provider Call

July 2023

Please place your name, and provider in the chat.

OKLAHOMA State Department of Health



Agenda

- State Data / COVID Administration Guidance
- COVID-19 Vaccine Ordering Update
- Vaccine Storage and Handling
- Vaccine Ordering & Distribution
- OSIIS Updates
- Guest Speaker

Dr. Savannah Stumph, DO FAAP Regional Medical Director, Merck Vaccines

- HPV
- Looking Forward

COVID-19 Vaccine State Data & Administration Guidance

Rishu Garg, Adult Vaccine Coordinator



COVID-19 VACCINATIONS IN OKLAHOMA – FEDERAL AND STATE (AS OF 5/10/2023)

2,961,991 people have received at least 1 dose* of the COVID-19 vaccine



2,399,774 people are fully vaccinated** with the COVID-19 vaccine

1,005,893 people have received a 3rd dose[^] or booster dose[^] of the COVID-19 vaccine

485,399 people have received the bivalent booster dose of the COVID-19 vaccine



Across Oklahoma, a total of **6,773,461 COVID-19 vaccine** doses have been administered since 12/14/2020


*Refers to eligible individuals receiving Pfizer and Moderna COVID-19 vaccines and/or receiving single shot of J&J/Janssen Vaccine; **Refers to eligible individuals (ages 5 years+) fully vaccinated after receiving either Pfizer and/or Moderna COVID-19 vaccines (both doses) and/or receiving single shot of J&J/Janssen Vaccine; ^3rd dose (Pfizer or Moderna) for individuals moderately to severely immunocompromised to be received at least 28 days after a second dose; ^Booster dose for individuals 65+ or certain other adults at high risk of severe COVID-19 to be received at least six months after completion of the primary mRNA vaccine series or two months after receiving single dose of J&J/Janssen vaccine.

Not for public distribution, data intended for internal planning purposes.

Data Source: CDC COVID Data Tracker - Tiberius Database. Data as of: May 10, 2023.

Recommended COVID-19 vaccines for **people without** immunocompromise, aged 6 months–4 years, mRNA vaccines, with vial icons and dosages, May 2023*[†]






*For administration intervals, see Table 1 in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

^tChildren who receive the Pfizer-BioNTech COVID-19 Vaccine and transition from age 4 yrs to 5 yrs during the 3-dose vaccination series must complete the series they start (i.e., receive the 0.2 ml/3 ug dosage supplied in vials with a maroon cap and label w/ maroon border for all 3 doses).

Recommended COVID-19 vaccines for **people without immunocompromise, aged 5 years,** mRNA vaccines, with vial icons and dosages, May 2023*[†]






*For administration intervals, see <u>Table 1</u> in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

^tChildren who transition from age 5 yrs-6 yrs during the Moderna vaccination series should receive 2 doses of Moderna COVID-19 Vaccine (0.25 ml/25 ug; dark blue cap and gray label & border.

Recommended COVID-19 vaccines for **people without** immunocompromise, aged 6 –11 years, mRNA vaccines, with vial icons and dosages, May 2023*






*For administration intervals, see <u>Table 1</u> in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Recommended COVID-19 vaccines for **people without immunocompromise, aged 12 years and older,** mRNA vaccines, *with vial icons and dosages,* May 2023*[†]






*For administration intervals, see <u>Table 1</u> in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

^tPeople ages 65 years and older have the option to receive 1 additional bivalent mRNA dose at least 4 months after the first dose of a bivalent mRNA vaccine.

Recommended COVID-19 vaccines for **people who ARE moderately or** severely immunocompromised, aged 6 months–4 years, mRNA vaccines, with vial icons and dosages, May 2023*






* For product and vaccination history-specific dosages, administration levels, and additional dose information see <u>Table 2</u> in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 5 years,** mRNA vaccines, *with vial icons and dosages,* May 2023*






* For product and vaccination history-specific dosages, administration levels, and additional dose information see <u>Table 2</u> in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 6 –11 years,** mRNA vaccines, *with vial icons and dosages,* May 2023*






* For product and vaccination history-specific dosages, administration levels, and additional dose information see <u>Table 2</u> in the Interim Clinical Considerations for Use of COVID-19 Vaccines.

Recommended COVID-19 vaccines for **people who ARE moderately or severely immunocompromised, aged 12 years and older,** with vial icons and dosages, mRNA vaccines, May 2023*





* For product and vaccination history-specific dosages, administration levels, and options for heterologous dosing, see <u>Table 2</u> in the Interim Clinical Considerations for Use of COVID-19 Vaccines.


Updated CDC Interim Clinical Considerations for Use of COVID-19 Vaccines in the U.S.

as of 6.29.23

The following COVID-19 vaccines, categorized into three vaccine types, are currently authorized under an <u>EUA</u> by FDA and available for use in the United States.

- mRNA vaccines
 - Moderna COVID-19 Vaccine, Bivalent
 - Pfizer-BioNTech COVID-19 Vaccine, Bivalent
- Protein subunit vaccine
 - Novavax COVID-19 Vaccine, Adjuvanted
- The *monovalent* formulations of the two mRNA COVID-19 vaccines (COMIRNATY/Moderna COVID-19 Vaccine and SPIKEVAX/Pfizer-BioNTech COVID-19 Vaccine) *should no longer be used for COVID-19 vaccination*.
- All currently available mRNA COVID-19 vaccines in the United States are formulated as a bivalent vaccine based on the original (ancestral) strain of SARS-CoV-2 and the Omicron BA.4 and BA.5 (BA.4/BA.5) variants of SARS-CoV-2.
- Novavax COVID-19 Vaccine is formulated as a monovalent vaccine based on the original (ancestral strain) of SARS-CoV-2.
- Janssen COVID-19 Vaccine is no longer available in the United States.

COVID-19 Vaccine Products in Use as of May 2023



COVID-19 vaccine-specific <u>FDA fact sheets</u> and <u>U.S. COVID-19 Vaccine Product Information</u> can be consulted for a full list of ingredients and information on the conditions of use, storage and handling, preparation, and administration procedures.



Pfizer-BioNTech COVID-19 Vaccine Formulation Guide

	Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) DILUTE BEFORE USE ¹	Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) DILUTE BEFORE USE ¹	Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) DO NOT DILUTE ¹		
Age Group	6 months through 4 years*	5 through 11 years* ("Age 5y to <12y" on vial label)	12 years and older		
Vial Cap Color	Maroon	Orange	Gray		
Dose	3 mcg	10 mcg	30 mcg		
Dose Volume	0.2 mL	0.2 mL	0.3 mL		
Amount of Diluent Needed per Vial [†]	2.2 mL [†]	1.3 mL†	NO DILUTION		
Doses per Vial [§]	Multiple Dose Vial: 10 doses per vial (after dilution)	Multiple Dose Vial: 10 doses per vial (after dilution)	Multiple Dose Vial:Single Dose Vial:6 doses per vial1 dose per vial		
		Storage Conditions			
Ultra-Low-Temperature (ULT) Freezer [-90 °C to -60 °C (-130 °F to -76 °F)]	18 months ⁱ	18 months [#]	18 months ⁱ		
Freezer [-25 °C to -15 °C (-13 °F to 5 °F)]	DO NOT STORE	DO NOT STORE	DO NOT STORE		
Refrigerator [2 °C to 8 °C (35 °F to 46 °F)]	10 weeks	10 weeks	10 weeks		
Room Temperature [8 °C to 25 °C (46 °F to 77 °F)]	12 hours prior to first puncture (including any thaw time) [‡]	12 hours prior to first puncture (including any thaw time) [≢]	12 hours prior to first puncture (including any thaw time) [#]		
After First Puncture [2 °C to 25 °C (35 °F to 77 °F)]	Discard after 12 hours [®]	Discard after 12 hours [¶]	Discard after 12 hours [¶]		



The complete formulation guide can be downloaded here: <u>https://webfiles.pfizer.com/formulation-guide</u> For more extensive information and guidance, including each formulation's EUA Fact Sheet: <u>https://www.cvdvaccine-us.com/</u>

Moderna COVID-19 Vaccine Formulations

Access Storage and Handling Information Here.

Vial cap color	BIVALENT B Pink capped vials with yellow-bordered label	BIVALENT Dark blue capped vial with gray- bordered label
Ages	6 months through 5 years	6 months and older
Beyond-use date/time	After first puncture, use within 8 hours	After first puncture, use within 12 hours
Do NOT use a punctured vial beyond-use date times.	If using a vial for the 1st time, record the date and time NOTE: The beyond-use time replaces the manufacture the earliest date. Do NOT use vaccine if the expiration	er's expiration date but NEVER extends it. Always use

Administration

- COVID-19 vaccine may be administered at the clinical visit Do NOT "pool" vaccine from more than 1 vial to obtain a as other other routinely recommended vaccines.
 - dose. If a full dose cannot be withdrawn, discard the vial and any remaining vaccine.
 - Gently swirl vaccine to mix. Do NOT shake.

Recipient's Age	Use	Administer	Route	Needle gauge and length	Site
6		Previously vaccinated with two	IM injection		6 months-2 years of age: Vastus lateralis muscle in the anterolateral thigh [*]
6 months through 5 years of age	Bivalent Pink capped vial with Yellow- bordered label	doses of Moderna COVID-19 Vaccine 10 μg/0.2 mL NOTE: This vial contains 2 doses.		22–25 gauge, 1"	3–5 years of age: Deltoid muscle in the upper arm [†]
6 months and older	Bivalent Dark blue	6 months–11 years: 25 μg/0.25 mL	ім	22–25 gauge,	6 months-2 years of age: Vastus lateralis muscle in the anterolateral thigh [*]
	bordered label	12 years and older: 50 μg/0.5 mL	injection	1–1½"	3 years and older: Deltoid muscle in the upper arm [†]

Interchangeability of COVID-19 vaccine products

- CDC recommends children ages 6 months—5 years who are unvaccinated and recommended to receive more than 1 bivalent mRNA vaccine dose for initial vaccination receive all doses from the same manufacturer. However, the FDA authorization allows for administration of a mixed product series for initial vaccination in some age groups.
- Authorization to use COVID-19 vaccines interchangeably from different manufacturers varies by vaccination history, age, and product as follows:
 - People ages 6 months—4 years who are unvaccinated or previously received 1 or more doses of a monovalent mRNA vaccine are authorized to receive only bivalent mRNA vaccine dose(s) from the same vaccine manufacturer.
 - People age 5 years who are unvaccinated or previously received 1 or more doses of monovalent Moderna COVID-19 Vaccine are authorized to receive either bivalent Moderna or bivalent Pfizer-BioNTech COVID-19 vaccine.
 - People age 5 years who are unvaccinated or previously received 1 or more doses of monovalent Pfizer-BioNTech COVID-19 are authorized to receive only bivalent Pfizer-BioNTech COVID-19 Vaccine.
 - People ages 6 years and older who are unvaccinated or previously received 1 or more doses of any monovalent COVID-19 vaccine are authorized to receive either bivalent Moderna or bivalent Pfizer-BioNTech COVID-19 vaccine.
- A <u>Vaccine Adverse Event Reporting System</u> (VAERS) report is required following administration of a vaccine in an unauthorized manner.
- In the following exceptional situations, a different age-appropriate COVID-19 vaccine may be administered when FDA authorization requires that a
 vaccine from the same manufacturer be used. A VAERS report is not required for these exceptional situations:
 - Same vaccine not available
 - Previous dose unknown
 - · Person would otherwise not complete the vaccination series
 - Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication



More information on the interchangeability of COVID-19 vaccine products for children and adolescents can be found here.

COVID- 19 Vaccine Ordering Updates





24

COVID-19 Vaccines available in OSIIS

- OSIIS offers 7 Covid-19 vaccines across all age groups.
- If you wish to order less than the minimum required dose amount, please specify the number of doses you would like to order under the clinic comments before submitting the order.
- Providers do have the option to opt-out of receiving ancillary kits with some COVID-19 Vaccine Orders.
 - Please note that Pfizer Pediatric vaccines orders *cannot* OPT-OUT from receiving ancillary kits.
 - If the "opt-out" option is greyed out on the OSIIS order page for any other vaccines, but you would like to opt-out from receiving them, please indicate this request in the clinic comments.

COVID-19 Vaccines available in OSIIS (cont.)

CVX	Name on OSIIS ordering page	NDC	Manufacturer	Minimum doses for direct-ship	Ancillary Opt-Out
211	Novavax COVID-19 (10 x 2.5mL Multi-Dose Vial)	80631-0102-10	NOVAVAX, INC	100	YES
229	COV-19 (Moderna); Bivalent; MDV5	80777-0282-99	MODERNA	100	YES*
230	MOD COVID-19 Bivalent Bstr 6m-5y (10 x 0.40mL MDV)	80777-0283-99	MODERNA	20	YES*
300	PFR COVID-19 Bivalent Bstr 12+yrs (10x2.0mL MDV)	59267-0304-02	PFIZER, INC.	180	YES*
300	PFR COVID-19 Bivalent Bstr 12+yrs (10x2.0mL SDV)	59267-1404-02	PFIZER, INC.	50	YES*
301	Pfizer COVID-19 Bivalent 5-11 yrs (10 x 2.0mL MDV)	59267-0565-02	PFIZER, INC.	100	NO, DUE TO DILUENT
302	Pfizer COVID-19 BIV Bivalent 6m-4y (10 x 2.6mL MDV)	59267-0609-02	PFIZER, INC.	100	NO, DUE TO DILUENT

*If you wish to opt-out from receiving ancillary kits with the order, please specify it under the clinic comments before submitting the order.


Vaccine Storage and Handling





Best Practice for Inventory Management

- To reduce waste, providers should be aware of vaccines in their inventory that are nearing expiration dates and prioritize their administration.
- Providers should enroll in the CDC Code Management Service to access the most up-to-date Expiration Information for all Vaccines.
 - Vaccine Lot Number and Expiration Date Webpage
 - Click the "Register" button in the upper right-hand corner to complete the registration form to request access.
- Moderna, Novavax, and Pfizer Vaccine Expiration Lookup & Reference Information:
 - Moderna Vial Expiration Data Look Up Tool
 - Pfizer-BioNTech Covid-19 Lot Expiry Tool
 - Novavax Expiry Date Checker Tool



Inventory Update Required Vaccine Finder, OSIIS

Failure to maintain an updated inventory may impact vaccine orders.

- Per the CDC, starting May 1st providers are required to update inventory in Vaccine Finder on a monthly basis.
- Inventory will be listed by vaccine name and age designation, *not* cap color.
- Training Videos and Guides:
 - https://www.vaccines.gov/covid-provider-resources/
- Step By Step Instructions:
 - <u>https://www.vaccines.gov/resources/QSG.for.Add.Vaccine.Flow_Clean_0</u>
 <u>6 04 21 FINAL.pdf</u>
 - For assistance in updating Vaccine Finder or OSIIS please call Immunization Services at (405) 426-8580.

Find COVID-19 Vaccines

Powered by VaccineFinder

5-digit Zip Code

Zip Code

Show COVID-19 Vaccines and Boosters

Pfizer-BioNTech (age 5-11)

Pfizer-BioNTech (age 12+)

Moderna (age 18+)

Johnson & Johnson/Janssen (age 18+)

View key details about which vaccine you should get

Show Only Locations That

Have appointments available

Search for COVID-19 Vaccines

<u>I'm looking for flu vaccines</u> →


Wastage

Do not return unused, open, spoiled, or expired COVID19 vaccines to manufacturers, distributors, OSDH, or CHD.

Discard all expired, wasted, and opened vials in the sharps container at the end of each day. Do not put open vials back into the fridge: adjust in OSIIS and discard at the end of the day.

COVID-19 vaccine program requirements include reporting wastage (unused, open, spoiled, or expired) into OSIIS. Please follow the Wastage tip sheet to report COVID-19 vaccine wastage.

After recording, the vaccine must be disposed in accordance with Oklahoma regulations and processes to dispose of regulated medical waste.





Covid-19 Vaccine Inventory Clean-Up

Following the end of the Public Health Emergency (PHE) Declaration on May 11th, 2023, we are asking providers to assess their inventory reporting data and account for unrecorded doses.

- Per <u>The CDC COVID-19 Vaccination Program Agreement</u>, providers are required to record vaccine administration in addition to the number of COVID-19 vaccine doses that were unused, spoiled, expired, or wasted. Providers are also required to dispose of expired COVID-19 vaccines in accordance with local regulations and processes regulating medical waste and report disposed vaccines as wastage.
 - Of note: ALL remaining monovalent mRNA vaccine formulations must be removed from inventory as they are no longer authorized.

To assess your facility's inventory reporting data and ensure accuracy, providers must take the following actions by **July 15th, 2023**:

- Review any unreported data and reconcile as needed.
- Adjust all monovalent, unused, spoiled, expired, or wasted vaccines from inventory in OSIIS
 - Select "VTRCKS-Other" as the adjustment reason
 - Enter "wastage" in the comment text box
- Zero out remaining inventory in Vaccine Finder according to previously established protocol.
- Dispose of expired COVID-19 vaccine in accordance with local regulations and processes regulating medical waste.

The <u>Operational Summary for Identifying, Disposing, and Reporting COVID-19 Vaccine Wastage I CDC</u> provides information to help awardees and immunization managers identify, handle, dispose of, and report waste in COVID-19 vaccination programs.

If you have any questions or concerns, please contact the OSIIS Help Desk or reach out to <u>Margaret.Archer@health.ok.gov</u> and <u>Muhammad.Khalil@health.ok.gov</u>

Vaccine Ordering and Distribution





Reconciliation

Reconciliation – weekly

- Providers are required to reconcile their inventory once during the ordering time frame: **Tuesday through Monday.**
- If a clinic does not reconcile COVID inventory for 7 days, they will not be able to create a vaccine order.
- An informational video on COVID 19 vaccine reconciliation and ordering can be accessed at <u>https://vimeo.com/528424790</u>
- Inventory Reconciliation





Ordering Process

- Providers can create orders in OSIIS during the ordering timeframe which is **Tuesday through Monday**.
- Vaccines can be ordered based on the need. If less than the minimum quantity is needed, providers will need to place an order for the minimum quantity and add a comment in the Clinic Comments indicating the number of doses needed.
- Providers now have the option to opt-out from receiving vaccine ancillary kits with their vaccine order. This doesn't apply for Pediatric Pfizer and Pediatric Pfizer Bivalent booster.
 - If you wish to opt-out, please specify this information in the Clinic Comments.
- Please do not refuse any vaccine shipments.

Clinic Comm	ents											
ONLY NE	ED 30	DOSES OF MODERN	IA.									
evx		Name	3	NDC	0	Manufacturer (Manufacturer	Cost per Package	Doses per Package	a Intent	Ancillary Kit	Qty of Packages
GVX	۹	NAME	Q	NDC	۹	MANUFA Q	MANUFA Q					
207		Moderna COVID-19 (10 5.0 mL MDV)	x 10 dose	80777-02	273-99	MOD	MODERNA	\$1.00	100	ADULT	v YES v	1



Ordering Process

- The cut-off to create orders in OSIIS Monday, 5pm.
- To make any changes or cancellations to orders after the deadline, providers must reach out ASAP.
 - To request a change, a provider should email to OSDH VaccineHelp <<u>VaccineHelp@health.ok.gov</u>>
 - If provider doesn't receive a confirmation of changes/cancellation within 24h, provider must call the OSDH Immunization Service 405.426.8580 to ensure that the order has been cancelled.
- Orders with at least min quantity, will be approved in OSIIS and directly shipped to providers subjected to CHANGE depending on the available weekly threshold amounts.
- Orders with less than min quantity will be rejected in OSIIS with a note that County Health Department (CHD) will fulfill the order and get in touch with the provider via email or phone.
 - Example of the message: "Your order will be fulfilled by your County Health Department. Watch for e-mail communication about the process and phone calls to arrange vaccine transfer."
 - CHDs will deliver vaccines to providers on the same or the following week. Delivered by CHD employees, national guard, or courier service.

Ordering Process

- Upon delivery of vaccine by CHD, the provider should complete 4 steps:
 - 1. Sign a Bill of Lading and keep a copy.
 - 2. Check that delivered vaccines are viable.
 - 3. Immediately place vaccines into storage according to <u>the guidelines</u> and label appropriately indicating expiration and/or Beyond-use dates (BUDs).

4. Accept transfer in OSIIS.

- Questions about orders:
 - OSIIS: OSIISHELP@health.ok.gov
 - Vaccine ordering process: VaccineHelp@health.ok.gov
 - Order fulfillment/delivery: Contact CHDs (contacts will be shared in the follow-up email).




OSIIS Updates

Martin Lansdale, MPH OSIIS Data Quality Coordinator



Updating Passwords in OSIIS







Request User Account

NOTICE: You are about to gain access to an Oklahoma State Department of Health application. By proceeding, you are agreeing that all information made available to you through this application will be kept confidential. Any unauthorized access, use, and/or disclosure of information received by you through this application is a violation of federal and state law and will result in a loss of access privileges, an action for civil damages, an action for criminal charges, and/or disciplinary action including, but not limited to, suspension or dismissal. This release of protected health information is pursuant to an individual request as authorized under 45 C.F.R. § 164.524, 63 O.S. § 1-502.2, and/or other federal and state statutes, rules, and regulations.

Public Portal- If you need a shot record, please use the OSIIS Public Portal to download a copy of your record.

NOTICE: To access OSIIS as a provider or clinic, all new providers/clinics have to sign an Authorized Site Agreement (ASA). Click on the following link to complete the ASA: OSIIS Authorized Site Agreement



Shot Records: Public Portal

- OSIIS has a public portal that can be found at the below link:
 - <u>https://osiis.health.ok.gov/osiis_public/Application/PublicPortal</u>
 - **DISCLAIMER:** Not all shots are recorded in OSIIS as reporting private vaccine is not required.
- Patients can search and download a copy of their shot record for just covid shots or their complete immunization history through the portal.
- The public portal uses **patient name, date-of-birth, email, and phone number** for verification purposes (all have to be on the shot record in OSIIS or patients cannot pull their shot record).
- Currently OSIIS has a high amount of missing emails/phone numbers.
- Providers need to make sure to document email and phone number for the patient <u>and</u> <u>add/send it to OSIIS</u> with the shot record in order to increase the likelihood of a records match in the portal.



News

WELCOME TO THE

Oklahoma State Immunization Information System

Default Provider/Clinic

Provider/Clinic : TEST PROVIDER ONE, TEST PROVIDER ONE

SELECT A CLINIC BY TYPING PROVIDER, CLINIC, VFC PIN, OR CLINIC CODE

News

[09/28/2022] - Update: Pediatric Bivalent Vaccine Formulations Pediatric Bivalent Vaccines

- Applications for Pfizer and Moderna Pediatric Bivalent products are currently under consideration.
 - Pfizer: Children aged 5 11 years. NDC (59267-0565-02)
 - Moderna: Children aged 6 17 years. More information will be released as it becomes available.
- Pending potential FDA EUA for the new Pediatric bivalent COVID-19 boosters, CDC's Advisory Committee on Immunization Practices (ACIP) will convene to discuss potential recommendations.
 - Once scheduled, ACIP meeting information is announced on the CDC website.
- · Both vaccines are expected to be approved for children who have already completed a primary series.
- Children will be eligible to receive a single bivalent Pfizer of Moderna booster if they received either of the following products:
 - Pfizer Adult Vaccine (children aged 12 17)
 - Moderna Vaccine (Children aged 12 17)
 - Pfizer Pediatric Vaccine (Children aged 5 11)

Pfizer Pediatric Bivalent

- For children aged 5 11
- New product with a new NDC



A

ж

Moderna Booster in OSIIS

Administer

Vaccination Time HH:MM AM/PM (HH:MI	M A/P)							
	Administered By *	Refusal Reason *						
Vaccine	TEST, TRAIN () 🗸	✓						
COVID-19 mRNA (MOD)	TEST, TRAIN () 🗸	Mfg Lot Exp Date (MM/DD/YY) Funding Src Inv Loc NDC Brand *						
		(I) MOD TEST1 04/21/22 PAN IITSTESTING2 80777-0273-99 MODERNA 🗸						
	Did not Admin 🗌	Body Site * Route * Dosage Refusal Reason						
	Delete	LD V INTRAMUSCULAR V 025						
	VFC: Not VFC							
	Eligible							



How To Guides

"How To" Guides

- Moderna Booster OSIIS Guide
- How to Turn On User Default Order Notifications
- Inventory Reconciliation
- How to Place a Covid-19 Vaccine Order
- Immunizing a Patient for COVID
- How to add an extra dose
- <u>Wastage</u>







Dr. Savannah Stumph, DO FAAP Regional Medical Director Merck Vaccines

Questions?

Thank you!





Questions/Suggestions

Looking Forward: Next Call October 6th, 2023 at 12pm



Resources: Medical Updates & Immunization Site Training for All Healthcare Providers led by Pfizer Vaccines US Medical Affairs

Goal: Educate providers and immunization staff personnel on the proper use of the Pfizer-BioNTech COVID-19 Vaccines To access dates and links for upcoming training sessions, please visit*:

https://www.pfizermedicalinformation.com/en-us/medical-updates



Resources

Testing:

- Nasopharyngeal, throat, saliva
- <u>Testing@health.ok.gov</u>

Monoclonal Antibodies: (Amanda Cavner)

- <u>Antivirals@health.ok.gov</u>
- <u>https://oklahoma.gov/covid19/what-you-should-know/monoclonal-antibody-therapies.html</u>

Vaccine:

- <u>COVID-19 Vaccines | FDA</u>
- PREP Act Guidance
- Interim Clinical Considerations for Use of <u>COVID-19 Vaccines | CDC</u>
- COVID-19 Vaccination for Children | CDC

- Pfizer: <u>Home (cvdvaccine-us.com)</u>
- Moderna: <u>What is Moderna COVID-19</u> <u>Vaccine (EUA)? | How Does It Work?</u> <u>(modernatx.com)</u>
- J&J: <u>Resources for COVID-19 Vaccine</u> <u>Education | Johnson & Johnson (jnj.com)</u>
- Novavax: <u>https://us.novavaxcovidvaccine.c</u> <u>om/hcp</u>



Resources/Tools

OSIIS Training: https://osiis.health.ok.gov/osiis/Application/ApplicationHelp/Index





Vaccine Inventory Adjustment: On-Hand Expired Vaccines

- When reconciling inventory, check that your facility has no expired inventory on hand.
 - Navigate to the Vaccine Inventory On-Hand screen by selecting:
 - Inventory > Vaccines > On-Hand from the left-hand menu.
- · Change the Status from On-Hand to Depleted/Expired
- Locate the Filter tab
- Locate the vaccine inventory item requiring an inventory adjustment.
- Click the corresponding **Action** button and select **Adjustment**.
 - Complete the following required fields:
 - **Date** (enter the actual date on which the inventory was wasted)
 - Reason (select Vtrcks Other)
 - **Modification** (if a value does not default, select Add or Subtract to make the corresponding adjustment)
 - **Doses Adjusted** (enter the number of doses wasted for the selected reason)
 - Comments (Expired)
- Click the Create button.
- Click the **On-Hand** menu item to return to the *Vaccine Inventory On-Hand* screen where you can verify the inventory was adjusted correctly.
- See attached video on Resources/Tools

QAs From Live Call

